Drug intelligence / Profile preview

Qiangli Ganmao

Development stage: Unknown
Lead developer: Shanghai Shyndec Pharmaceutical
Administration: Oral

Overview

Qiangli Ganmao (强力感冒) is a Traditional Chinese Medicine (TCM) product developed and manufactured by Shanghai Shyndec Pharmaceutical, a subsidiary of Sinopharm (China National Pharmaceutical Group). It is approved in China for the treatment of pharyngitis and symptoms associated with the common cold. As a TCM formulation, it consists of a proprietary blend of herbal ingredients designed to alleviate respiratory discomfort and inflammation. The drug is part of Shyndec's extensive portfolio of anti-infective and respiratory treatments, though detailed information regarding its specific chemical composition and biological targets is limited in standard clinical databases.

Brand names: Qiangli Ganmao
Other names: 强力感冒

Beyond the preview

Go deeper on Qiangli Ganmao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiangli Ganmao.

Explore the full profile